

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-26. (Cancelled)

27. (Currently Amended): A physicochemically stable aqueous composition for oral administration comprising clozapine in suspension, a wetting agent, and a buffer, wherein the pH of the composition is maintained within the range of about 6 to about 11.

28. (Cancelled)

29. (Cancelled)

30. (Previously Presented): The composition according to claim 27 wherein the buffer is a sodium phosphate/sodium hydroxide buffer.

31. (Previously Presented): The composition according to claim 27 wherein the pH is maintained in the range of from about 6 to about 8.

32. (Previously Presented): The composition according to claim 27 wherein the amount of clozapine in the composition is from about 0.1% to about 10% by weight based on the total volume of the composition.

33. (Cancelled)

34. (Previously Presented): The composition according to claim 27 comprising a wetting agent in an amount of between about 0.1% and about 15%.

35. (Previously Presented): The composition according to claim 27 comprising a wetting agent

selected from any one or more of propylene glycol, glycerin, or polyethylene glycol.

36. (Previously Presented): The composition according to claim 27 wherein the composition includes a suspending agent and/or a preservative.

37. (Previously Presented): The composition according to claim 27 comprising a preservative selected from any one or more of methyl, propyl and butyl parabens.

38. (Previously Presented): The composition according to claim 27 wherein the composition includes: clozapine, glycerine, sodium dihydrogen phosphate dihydrate/NaOH buffer, xanthan gum, methyl paraben, propyl paraben, butyl paraben, and water.

39. (Withdrawn): A method for preparing a physicochemically stable aqueous composition including clozapine in suspension, the method comprising the step of controlling the pH of the formulation between about 6 and about 11.

40. (Withdrawn): The method according to claim 39 wherein the pH is controlled between 6 and 8.

41. (Withdrawn): The method according to claim 39 wherein the method further includes the addition of PVP.

42. (Withdrawn): A method of producing a physicochemically stable aqueous composition comprising clozapine in suspension comprising the following steps:

- (a) stirring the clozapine with about three quarters of the propylene glycol ascribed to the batch;
- (b) addition of the buffer salt (and optionally sweetening agents) dissolved in about half the volume of water ascribed to the batch with constant stirring;
- (c) adjusting the pH value with the base component of the buffer with mixing;

Application No. 10/561,930
Amendment Dated 2/14/2011
Reply to Office Action of 10/29/2010

- (d) addition of the preservatives dissolved in the remaining propylene glycol;
- (e) slow addition of the suspending agent with continuous stirring until the mixture thickens; and,
- (f) further diluting the suspension with water to the desired end-volume.

43. (Withdrawn): A method for producing a physicochemically stable aqueous composition comprising clozapine in suspension comprising the following steps:

- (a) stirring the clozapine with about three quarters of the glycerine ascribed to the batch;
- (b) addition of the buffer salt (and optionally sweetening agents) dissolved in about half the volume of water ascribed to the batch with constant stirring;
- (c) adjusting the pH value with the base component of the buffer with mixing;
- (d) addition of the preservatives dissolved in a small volume of water;
- (e) slow addition of the suspending agent wetted with the remaining glycerine with continuous stirring until the mixture thickens; and,
- (f) further diluting the suspension with water to the desired end-volume.

44. (Withdrawn): The method according to claim 42 wherein PVP is added as an aqueous solution following addition of the suspending agent.

45. (Withdrawn): The method according to claim 43 wherein PVP is added as an aqueous solution following addition of the suspending agent.

46. (Previously Presented): The composition according to claim 27 wherein the composition further includes a sweetening agent and/or a flavoring substance.

47. (Currently Amended): A physicochemically stable aqueous composition for oral administration comprising clozapine in suspension, and a wetting agent, wherein the pH of the composition is maintained using a buffer.

48. (Currently Amended): A physicochemically stable aqueous composition for oral administration comprising clozapine in suspension, and a wetting agent, wherein the pH of the composition is maintained within the range of about 6 to about 11.

49. (Currently Amended): The composition according to claim 47 or 48, further comprising a preservative.

50. (Currently Amended): The composition according to claim 47 or 48, further comprising a sweetening agent.

51. (New): The composition according to claim 47 or 48, wherein the wetting agent is present in an amount of between about 0.1% and about 15%.

52. (New): The composition according to claim 47 or 48, wherein the wetting agent is selected from any one or more of propylene glycol, glycerin, and polyethylene glycol.

53. (New): The composition according to claim 27 wherein the composition comprises: clozapine, glycerin, sodium dihydrogen phosphate dihydrate/NaOH buffer, xanthan gum, sodium methyl paraben, sodium propyl paraben and water.

54. (New): The composition according to claim 47 or 48 wherein the composition comprises: clozapine, glycerin, xanthan gum, sodium methyl paraben, sodium propyl paraben and water.

55. (New): The composition according to claim 27 wherein the composition is stable for at least 14 months.

56. (New): The composition according to claim 47 or 48 wherein the composition is stable for at least 14 months.